201 related articles for article (PubMed ID: 38288438)
1. The adverse events of CDK4/6 inhibitors for HR+/ HER2- breast cancer: an umbrella review of meta-analyses of randomized controlled trials.
Pu D; Wu Y; Xu D; Shi G; Chen H; Feng D; Zhang M; Li J
Front Pharmacol; 2024; 15():1269922. PubMed ID: 38288438
[No Abstract] [Full Text] [Related]
2. Comparative efficacy and safety of CDK4/6 inhibitors combined with endocrine therapies for HR+/HER2-breast cancer: Systematic review and network meta-analysis.
Tong F; Lu Y; Ma HF; Shen J
Heliyon; 2024 Jun; 10(11):e31583. PubMed ID: 38832268
[TBL] [Abstract][Full Text] [Related]
3. Side effects of CDK4/6 inhibitors in the treatment of HR+/HER2- advanced breast cancer: a systematic review and meta-analysis of randomized controlled trials.
Yang L; Xue J; Yang Z; Wang M; Yang P; Dong Y; He X; Bao G; Peng S
Ann Palliat Med; 2021 May; 10(5):5590-5599. PubMed ID: 34107710
[TBL] [Abstract][Full Text] [Related]
4. Real world incidence and management of adverse events in patients with HR+, HER2- metastatic breast cancer receiving CDK4 and 6 inhibitors in a United States community setting.
Price GL; Sudharshan L; Ryan P; Rajkumar J; Sheffield KM; Nash Smyth E; Morato Guimaraes C; Rybowski S; Cuyun Carter G; Gathirua-Mwangi WG; Huang YJ
Curr Med Res Opin; 2022 Aug; 38(8):1319-1331. PubMed ID: 35535675
[TBL] [Abstract][Full Text] [Related]
5. The likelihood of being helped or harmed as a patient-centred tool to assess cyclin dependent kinase 4/6 inhibitors clinical impact and safety in metastatic breast cancer: a systematic review and sensitivity-analysis.
Mastrantoni L; Orlandi A; Palazzo A; Garufi G; Fabi A; Daniele G; Giannarelli D; Tortora G; Bria E
EClinicalMedicine; 2023 Feb; 56():101824. PubMed ID: 36713467
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of CDK4/6 inhibitors combined with endocrine therapy in HR+/HER2- breast cancer: an umbrella review.
Pu D; Xu D; Wu Y; Chen H; Shi G; Feng D; Zhang M; Liu Z; Li J
J Cancer Res Clin Oncol; 2024 Jan; 150(1):16. PubMed ID: 38240835
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant and neoadjuvant therapy with cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: a systematic review and meta-analysis.
Zhang M; Song J; Guo S; Jin F; Zheng A
Endocr Relat Cancer; 2023 Aug; 30(8):. PubMed ID: 37283514
[TBL] [Abstract][Full Text] [Related]
8. Association of Cyclin-Dependent Kinases 4 and 6 Inhibitors With Survival in Patients With Hormone Receptor-Positive Metastatic Breast Cancer: A Systematic Review and Meta-analysis.
Li J; Huo X; Zhao F; Ren D; Ahmad R; Yuan X; Du F; Zhao J
JAMA Netw Open; 2020 Oct; 3(10):e2020312. PubMed ID: 33048129
[TBL] [Abstract][Full Text] [Related]
9. CDK4/6 inhibitors in advanced hormone receptor-positive/HER2-negative breast cancer: a systematic review and meta-analysis of randomized trials.
Messina C; Cattrini C; Buzzatti G; Cerbone L; Zanardi E; Messina M; Boccardo F
Breast Cancer Res Treat; 2018 Nov; 172(1):9-21. PubMed ID: 30054831
[TBL] [Abstract][Full Text] [Related]
10. Hematological toxicity of cyclin-dependent kinase 4/6 inhibitors in patients with breast cancer: a network meta-analysis and pharmacovigilance study.
Ding H; Xu W; Dai M; Li S; Xin W; Tong Y; He C; Mi X; Zhan Z; Fang L
Expert Opin Drug Saf; 2024 May; ():1-9. PubMed ID: 38753541
[TBL] [Abstract][Full Text] [Related]
11. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
12. Pharmacoeconomic evaluations of CDK4/6 inhibitors plus endocrine therapy for advanced hormone receptor-positive (HR+) and human epidermal growth factor receptor-2 negative (HER2-) breast cancer: a systematic review.
Zhu L; Wang M; Luo X; Li H; Shan H; Du Q; Zhai Q
Ann Transl Med; 2022 Feb; 10(4):233. PubMed ID: 35280368
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant CDK4/6 inhibitors combined with endocrine therapy in HR-positive, HER2-negative early breast cancer: A meta-analysis of randomized clinical trials.
Gao HF; Lin YY; Zhu T; Ji F; Zhang LL; Yang CQ; Yang M; Li JQ; Cheng MY; Wang K
Breast; 2021 Oct; 59():165-175. PubMed ID: 34271289
[TBL] [Abstract][Full Text] [Related]
14. Cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer: a meta-analysis of randomized clinical trials.
Li J; Fu F; Yu L; Huang M; Lin Y; Mei Q; Lv J; Wang C
Breast Cancer Res Treat; 2020 Feb; 180(1):21-32. PubMed ID: 31970560
[TBL] [Abstract][Full Text] [Related]
15. CDK4/6 Inhibitors in Combination With Hormone Therapy for HR
Deng Y; Ma G; Li W; Wang T; Zhao Y; Wu Q
Clin Breast Cancer; 2018 Oct; 18(5):e943-e953. PubMed ID: 29804650
[TBL] [Abstract][Full Text] [Related]
16. Comparative Overall Survival of CDK4/6 Inhibitors Plus Endocrine Therapy vs. Endocrine Therapy Alone for Hormone receptor-positive, HER2-negative metastatic breast cancer.
Lin M; Chen Y; Jin Y; Hu X; Zhang J
J Cancer; 2020; 11(24):7127-7136. PubMed ID: 33193875
[No Abstract] [Full Text] [Related]
17. Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: A network meta-analysis.
Desnoyers A; Nadler MB; Kumar V; Saleh R; Amir E
Cancer Treat Rev; 2020 Nov; 90():102086. PubMed ID: 32861975
[TBL] [Abstract][Full Text] [Related]
18. CDK4/6 Inhibitors Expand the Therapeutic Options in Breast Cancer: Palbociclib, Ribociclib and Abemaciclib.
Eggersmann TK; Degenhardt T; Gluz O; Wuerstlein R; Harbeck N
BioDrugs; 2019 Apr; 33(2):125-135. PubMed ID: 30847853
[TBL] [Abstract][Full Text] [Related]
19. CDK4/6 inhibitors as adjuvant treatment for hormone receptor-positive, HER2-negative early breast cancer: a systematic review and meta-analysis.
Agostinetto E; Vian L; Caparica R; Bruzzone M; Ceppi M; Lambertini M; Pondé N; de Azambuja E
ESMO Open; 2021 Apr; 6(2):100091. PubMed ID: 33743330
[TBL] [Abstract][Full Text] [Related]
20. Comparative efficacy and safety of different combinations of three CDK4/6 inhibitors with endocrine therapies in HR+/HER-2 - metastatic or advanced breast cancer patients: a network meta-analysis.
Liu Y; Wu J; Ji Z; Chen L; Zou J; Zheng J; Lin W; Cai J; Chen Y; Zheng D; Chen Y; Li Z
BMC Cancer; 2023 Aug; 23(1):816. PubMed ID: 37653504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
